A randomized, open-label study of the tolerability and efficacy of one or three daily doses of ivermectin plus diethylcarbamazine and albendazole (IDA) versus one dose of ivermectin plus albendazole (IA) for treatment of onchocerciasis
Published: 12 May 2023| Version 1 | DOI: 10.48765/xq0p-e188
Contributors:
, , , Felix Doe, , , , , , , , , , , , , Description
Data collected from participants at during a clinical trial in Hohoe, Ghana where participants are identified by a unique participant ID. There are two datasets. The Safety dataset includes demographics, skin snip results, adverse event results, and ophthalmological data from baseline, day of treatment, Day 1-7, Month 3, Month 12, and Month 18. The Nodulectomy data set contains data pertaining to sectioned nodules read by scientists at 18 months which indicate embryogenesis in female worms, number of male and female worms, and worm calcification.
Files
Institutions
Case Western Reserve University, University of Health and Allied Sciences, Washington University in St. Louis, Universitatsklinikum Bonn, University of Ghana
Categories
Medicine, Health Sciences, Parasitic Disease
Funding
Bill and Melinda Gates Foundation
OPP1190749
Additional Metadata for Digital Commons Data@Becker
| Keywords | Communicable Disease, Tropical Medicine, Onchocerciasis, Onchocerca Volvulus, Microfilariae, Helminths, Nematoda, Filaricides, Ivermectin, Albendazole, Clinical Trial, Ophthalmology, Eye Diseases, Western Africa, Ghana, Diethylcarbamazine |
| Other Contributing Institutions | Hohoe Municipal Hospital, St. Thomas Eye Hospital |